<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

CCG 232601

產(chǎn)品貨號

Axon 2753 CAS [1922099-21-5] MF C24H20ClF2N3O2MW 455.88 Purity: 99% Soluble in DMSO Description Inhibitor of the Rho/MRTF/SRF signaling pathway (IC50 value of 0.55 μM (SRE.L assay)) as potential antifibrotic therapeutic for systemic scleroderma. CCG-232601 inhibited the development of bleomycin-induced dermal fibrosis in mice when administered orally. KEYWORDS: CCG 232601 | supplier | Rho/MRTF/SRF inhibitor | CCG-232601 | CCG232601 | CAS [1922099-21-5] | Non Selective (Phosphorylation Substrates) | ROCK | Inhibitor | Enzymes | Scleroderma | Sclerosis | Antifibrotic

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

CCG 232601

Based on 1 reference(s) in Google Scholar 8 10 1

Axon 2753

CAS [1922099-21-5]

MF C24H20ClF2N3O2
MW 455.88

Purity: 99%
Soluble in DMSO

CCG 232601

Description

Inhibitor of the Rho/MRTF/SRF signaling pathway (IC50 value of 0.55 μM (SRE.L assay)) as potential antifibrotic therapeutic for systemic scleroderma. CCG-232601 inhibited the development of bleomycin-induced dermal fibrosis in mice when administered orally.

KM Hutchings et al. Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1744-1749.

Certificate of Analysis
Material Safety Data Sheet

Immunology Pain & Inflammation ROCK Transcription Factors TGF-β EC 2.7.11.1

Rho/MRTF/SRF transcriptional pathway inhibitor

Chemical name

N-(4-Chlorophenyl)-5,5-difluoro-1-(3-(pyridin-4-yl)benzoyl)piperidine-3-carboxamide

Parent CAS No.

[1922099-21-5]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>